Articles

“It is time for paediatric ophthalmologists to reassess how best to screen and treat their smallest, frailest patients,” said Dr. John Flynn of Columbia University School of Medicine, speaking at the Paediatric Ophthalmology symposium, being held alongside the AAO in San Francisco.

Allergan Inc. has won a ruling in federal court that its patents on Alphagan, which lowers pressure in the eye in patients with open-angle glaucoma and ocular hypertension, were infringed.

STAAR Surgical Company has reported that the Collamer Accommodating Study Team (CAST) formed by the company in late 2008 has provided very promising initial patient vision assessments from the first phase of the project.

Real-time biomedical studies of factors leading to vision impairment are now possible through one of the world's largest ocular research centre at Lions Eye Institute for Transplant & Research.

In Ophthalmology V Borderie et al., analyze graft survival and the outcome of the corneal endothelium after corneal transplantation in a single model to predict the long-term prognosis of these grafts

Two Phase III studies of Lucentis (ranibizumab injection) in macular oedema due to retinal vein occlusion (RVO), have shown, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented at the Retina Congress 2009 meeting.

According to M Rekas et al., in The Journal of Cataract & Refractive Surgery torsional phacoemulsification was found to be more effective than longitudinal phacoemulsification in the amount of applied fluid and the quantity of US energy expended.

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

According to the Review of OphthalmologyRefinements in tools and technique are leading to better outcomes, fewer complications and promising new versions of the surgery.

Bausch & Lomb, has acquired the commercial assets of Italian ophthalmic pharmaceuticals business, Tubilux Pharma S.p.A, which markets proprietary, over-the-counter and branded generic products.

Following intrastromal corneal ring sement implantation five years ago for the management of keratoconus, The Journal of Cataract & Refractive Surgery has published long-term follow up results.

Optical Coherence Tomography (OCT) in Age-Related Macular Degeneration (AMD) comes under the spotlight in a new book by Professor Gabriel Coscas.

LX214, a topical mixed nanomicellar formulation of voclosporin, has completed its Phase 1 human safety and an open-label pilot efficacy study and is being heralded by its maker Lux Biosciences as a promising treatment for dry eye.

Dr Jorge Alio, a valued member of Ophthalmology Times Europe?s Editorial Advisory Board, has been acknowledged by The Cornea Research Foundation of America (CRFA) for his technique using Yag laser treatments to eliminate epithelial ingrowth after Lasik.

Bromfenac ophthalmic solution will come to Europe when it comes to market thanks to a co-promotion between Bausch & Lomb and CROMA Pharma.

This is the first ESCRS congress for 9-month old company, Technolas, which was formed out of a joint venture between Bausch and Lomb's refractive surgery unit and 20/10 Perfect Vision. The new business was founded to innovate in excimer and femtosecond laser technologies, focusing primarily on the correction of presbyopia.

Schwind unveiled its PresbyMAX software module at ESCRS, a presbyopia solution for its AMARIS system. According to Schwind, the software makes it possible, for the first time, to treat emmetropic as well as myopic, hyperopic and astigmatic patients whose accommodative response is limited.

Breaking news from Day 4 of ESCRS

Ziemer has launched a new corneal surgery model to expand the capabilities of its LDV Femtosecond laser system.

Improved visualization of the eye&39;s anatomy is the aim of a new series of high-resolution micro-endoscopes from Endo Optiks.

Technique intra-operative findings and postoperative regimen

The Flexivue System, a breakthrough implantable micro-lens treatment for presbyopia from Presbia Coöperatief was unveiled at the show and it is keenly anticipated that it will be in clinical trials in several European countries by the end of the year.

Supervision: Myth and Reality

The news broke at today's show that Alcon is to gain access to proprietary antibody fragment technology particularly suited to treat eye diseases with its plan to acquire ESBATech AG, a Swiss biotechnology firm.

Rayner, the world's first IOL manufacturer, unveiled a dynamic new brand identity at ESCRS and held a seminar today to highlight the success doctors are having with its range of toric IOLs. Headlined A Roadmap to Success the seminar featured presentations from seven European doctors relating their experiences of using Rayner's toric IOLs.

Combind cataract and vitreoretinal surgery

A review of the role and efficacy of anti-VEGF therapy in macular disease

Cataract surgery in patients with pre-existing AMD: Risks and Benefits

Breaking news from Day 2 of ESCRS

New insights into ectopia lentis